Drugging hijacked kinase pathways in pediatric oncology: opportunities and current scenario (2023)
Fonte: Pharmaceutics. Unidades: FMRP, FFCLRP
Assuntos: NEOPLASIAS, CRIANÇAS, INIBIDORES QUÍMICOS, PROTEÍNAS QUINASES
ABNT
CÂNDIDO, Marina Ferreira et al. Drugging hijacked kinase pathways in pediatric oncology: opportunities and current scenario. Pharmaceutics, v. 15, n. 2, p. 1-87, 2023Tradução . . Disponível em: https://doi.org/10.3390/pharmaceutics15020664. Acesso em: 04 nov. 2024.APA
Cândido, M. F., Medeiros, M., Veronez, L. C., Bastos, D., Oliveira, K. L., Pezuk, J. A., et al. (2023). Drugging hijacked kinase pathways in pediatric oncology: opportunities and current scenario. Pharmaceutics, 15( 2), 1-87. doi:10.3390/pharmaceutics15020664NLM
Cândido MF, Medeiros M, Veronez LC, Bastos D, Oliveira KL, Pezuk JA, Valera ET, Annichini MSB. Drugging hijacked kinase pathways in pediatric oncology: opportunities and current scenario [Internet]. Pharmaceutics. 2023 ; 15( 2): 1-87.[citado 2024 nov. 04 ] Available from: https://doi.org/10.3390/pharmaceutics15020664Vancouver
Cândido MF, Medeiros M, Veronez LC, Bastos D, Oliveira KL, Pezuk JA, Valera ET, Annichini MSB. Drugging hijacked kinase pathways in pediatric oncology: opportunities and current scenario [Internet]. Pharmaceutics. 2023 ; 15( 2): 1-87.[citado 2024 nov. 04 ] Available from: https://doi.org/10.3390/pharmaceutics15020664